Senolytics—a class of drugs that reduce chronic inflammation and tissue damage in aging cells—are shown to eliminate 30% to 70% of "zombie" cells in the body. These zombie cells, known as senescent ...
SEATTLE -- A drug targeting senescent cells in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) produced mixed outcomes in two separate clinical trials. The 48-week ...
Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — A senolytic therapy represents a novel approach to treating diabetic macular edema and ...
NEW YORK CITY -- An investigational drug targeting senescent cells achieved sustained improvement in visual acuity in patients with diabetic macular edema (DME) or neovascular age-related macular ...
Senolytics are an emerging class of drugs designed to target zombie-like cells that have stopped dividing and build up in the body as we age, and the past few years have seen some exciting discoveries ...
MIAMI, Sept. 24, 2025 /PRNewswire/ -- Immorta Bio, Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," today announced the filing of a U.S.
Researchers from Juntendo University, Japan examine the molecular mechanisms underlying the senolytic or senescent cell removal effects of the the sodium glucose co-transporter 2 inhibitor and its ...
A new research paper was published by Aging (Aging-US) on January 8, 2025, in Volume 17, Issue 1, titled "Senolytic agent ABT-263 mitigates low- and high-LET radiation-induced gastrointestinal cancer ...
In a recent study published in Nature Medicine, researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results